桑艳芳 郝贺玲 郭菲菲 孙向荣 公衍玲 徐珞.下丘脑Orexin 对肥胖大鼠能量代谢的影响[J].现代生物医学进展英文版,2016,16(29):5625-5629. |
下丘脑Orexin 对肥胖大鼠能量代谢的影响 |
The Effects of Hypothalamic Administration of Orexin on Metabolismin Diet-induced Obese Rats |
|
DOI: |
中文关键词: 肥胖 代谢综合征 ACT-335827 脂代谢 |
英文关键词: Obesity Metabolic Syndrome ACT-335827 Lipid Metabolism |
基金项目:国家自然科学基金项目(81470815,81500414,8
1100260,8
1270460,81300281);青岛市科技局项目(13-1-4-170-jch,11-2-3-3-(2)-nsh) |
|
Hits: 858 |
Download times: 0 |
中文摘要: |
目的:探讨下丘脑注射OXR-1 选择性受体拮抗剂ACT-335827 对肥胖大鼠代谢的效果。方法:通过高脂饮食建立肥胖大鼠
模型,采用CODA 8通道高通量非侵入性血压系统(EMKA)测量血压;所有脂类都使用商品酶试剂盒和TOSHIBA-40FR 全自动分
析仪测量;空腹血糖采用葡萄糖氧化酶法;空腹胰岛素采用放射免疫法测定。肥胖大鼠出现代谢紊乱后,给予ACT-335827 处理,
检测大鼠体重、血压、脂肪、甘油三酯、总胆固醇、高密度脂蛋白、低密度脂蛋白、游离脂肪酸(NEFA)、瘦素、空腹血糖及空腹胰岛素
等的变化。结果:与普通饮食组相比,经过10周高脂饮食,高脂饮食组大鼠体重显著升高(P<0.05),给予ACT-335827 处理后,普通
大鼠的体重、血压、脂肪含量、脂代谢等均无明显变化;与高脂饮食和高脂饮食加生理盐水处理组大鼠比较,高脂饮食加
ACT-335827 处理组肥胖大鼠的体重显著下降(P<0.05),腹部和附睾脂肪含量下降(P<0.05),低密度脂蛋白、甘油三酯、总胆固醇、
瘦素水平下降(P<0.05),空腹血糖及空腹胰岛素也显著降低(P<0.05),但血压、肠系膜脂肪和肩胛棕色脂肪、高密度脂蛋白和NEFA
无明显变化(P<0.05)。结论:ACT-335827 对肥胖大鼠的代谢紊乱具有改善作用,对肥胖大鼠有一定的减肥作用。 |
英文摘要: |
Objective:To investigate the effects of hypothalamic administration of OXR-1 selective antagonist ACT-335827 on
the metabolism of high-fat diet induced obese rats.Methods:Obese rat model was established by high fat diet feeding. Blood pressure
was indirectly measured by blood volume pressure recording (VPR) from the tail using the CODA 8-channel high throughput non-invasive
blood pressure system (EMKA). All plasma lipids were measured using commercial enzyme assay kits and a TOSHIBA-40FR fully
automated analyzer. Fasting blood glucose was measured using glucose oxidase kit. Fasting insulin was measured by radioimmunoassay.
When obese rats displayed metabolic disorders, ACT-335827 was given for the treatment. The changes in body weight, blood pressure,
fat, plasma triglycerides, total cholesterol, high density lipoprotein, low density lipoprotein, non-esterified fatty acid (NEFA), leptin, fasting
blood glucose and fasting insulin were measured.Results:Compared with standard chow groups, the body weight of rats in high-fat
diet groups were significantly increased after 10 weeks of high fat diet feeding (P<0.05). After ACT-335827 treatment, the body weight,
blood pressure, fat content and lipid metabolism of rats in standard chow groups did not change significantly (P>0.05); compared with
high-fat diet group and high-fat diet with normal saline treatment group, the body weight of high fat diet feeding rats with ACT-335827
treatment was significantly decreased (P<0.05). Similarly, the abdominal and epididymal fat content were decreased (P<0.05); low-density
lipoprotein, triglycerides, total cholesterol and leptin levels were decreased (P<0.05); fasting glucose and fasting insulin were significantly
reduced (P<0.05) in high-fat diet feeding rats with ACT-335827 treatment. However, blood pressure, mesenteric fat and scapular brown
fat, high-density lipoprotein and NEFA of these rats were not remarkably changed (P<0.05).Conclusion:ACT-335827 could improve
the metabolic disorders in high fat induced obese rats, and ACT-335827 may play a role in weight loss in high fat induced obese rats. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|